Indianapolis-based Eli Lilly and Co. officially emerged Monday as the $70-per-share bidder for ImClone Systems Inc., affirming last week's speculation on the Street, as it aims to pick up a pipeline that includes marketed EGFR inhibitor Erbitux and three late-stage oncology programs. (BioWorld Today) Read More
